While CDK4/6 inhibitors have become standard of care in patients with HR+/HER2- advanced breast cancer (ABC), selecting the optimal inhibitor could improve care further. Here, the authors report planned interim analysis of the BRIGHT-2 study, a randomised phase 3 trial comparing bireociclib (CDK4/6i) and fulvestrant (ET) against placebo and fulvestrant in female HR + /HER2- ABC patients.
- Jiayu Wang
- Qingyuan Zhang
- Binghe Xu
